{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:23:44Z","timestamp":1791498224606,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.urolonc.2023.09.010","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T15:48:02Z","timestamp":1697471282000},"page":"21.e21-21.e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-5628","authenticated-orcid":false,"given":"Adri M.","family":"Durant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouneeb M.","family":"Choudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Madura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanyu","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassem S.","family":"Faraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.09.010_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0002","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0004","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.5489\/cuaj.1196","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"J Can Urol Assoc"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0005","first-page":"423","article-title":"Failure of bacillus Calmette-Gu\u00e9rin therapy in non-muscle-invasive bladder cancer: definition and treatment options","volume":"69","author":"Frau","year":"2016","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0006","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer: a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/256985","article-title":"Management of bladder cancer following solid organ transplantation","volume":"2011","author":"Tomaszewski","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2490-9-10","article-title":"HIV-associated bladder cancer: A case series evaluating difficulties in diagnosis and management","volume":"9","author":"Gaughan","year":"2009","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1034\/j.1399-0012.2002.01152.x","article-title":"The outcome of post-transplant transitional cell carcinoma in 10 renal transplant recipients","volume":"16","author":"Ben","year":"2002","journal-title":"Clin Transplant"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1464-410X.2007.07210.x","article-title":"Bladder carcinoma among live-donor renal transplant recipients: a single-centre experience and a review of the literature","volume":"101","author":"Kamal","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0012","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2009.06.106","article-title":"Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the french department of urology and kidney transplantation from Bordeaux","volume":"75","author":"Elkentaoui","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0013","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.urology.2012.11.035","article-title":"Management of bladder cancer after renal transplantation","volume":"81","author":"Prabharasuth","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0014","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/01.TP.0000090748.32764.0F","article-title":"Intravesical bacillus Calmette-Gu\u00e8rin for the treatment of superficial bladder cancer in renal transplant patients","volume":"76","author":"Palou","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696268","article-title":"Case report: acquired disseminated BCG in the context of a delayed immune reconstitution after hematological malignancy","volume":"12","author":"Gies","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0016","first-page":"e9035","article-title":"A 25-year surveillance of disseminated Bacillus Calmette-Gu\u00e9rin disease treatment in children in Southern Iran","volume":"96","author":"Amanati","year":"2017","journal-title":"Med (United States)"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0017","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: Recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0018","first-page":"165.e17","article-title":"Defining radical cystectomy using the ICD-10 procedure coding system","volume":"40","author":"Lyon","year":"2022","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0019","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0021","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1464-410X.2012.11778.x","article-title":"Intravesical Bacille Calmette-Gu\u00e9rin (BCG) in immunologically compromised patients with bladder cancer","volume":"111","author":"Herr","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0022","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.juro.2006.03.066","article-title":"Safety and efficacy of intravesical Bacillus Calmette-Guerin Instillations in steroid treated and immunocompromised patients","volume":"176","author":"Yossepowitch","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0023","first-page":"108e1","article-title":"BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study","volume":"33","author":"Herr","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0024","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.09.010_bib0025","unstructured":"National Institutes of Health, Bethesda M. Autoimmune Disease Coordinating Committee Report. 2002."},{"key":"10.1016\/j.urolonc.2023.09.010_bib0026","unstructured":"National Cancer Institute. Measures that are limited or not available in the data. Divison of Cancer Control & Population Science Healthcare Delivery Research Program n.d. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/measures.html#13."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392300323X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392300323X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:40Z","timestamp":1761042460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392300323X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S107814392300323X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.09.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}